Proteasomal dysfunction in the AD brain has been shown to result from the inhibitory binding of filamentous tau to proteasomes [14], and a recent study found that tau-driven proteasome impairment occurs in a mouse model of tauopathy [15]. The gene discussed is MAPT; the disease is tauopathy.